Amendment to exclusive patent, know-how and technology to make, have made, use, sell, offer, export, import, label, package and sublicense products related to LHRH antagonist compounds for all human therapeutic, prophylactic and diagnostic uses, including prostrate cancer and endometriosis indications, but excluding veterinary uses.

This document is an amendment to an exclusive patent and know-how agreement covering LHRH antagonist compounds for various human therapeutic, prophylactic, and diagnostic uses. The text primarily serves as a promotional overview of RoyaltyStat®, an online database used by professionals for transfer pricing and intellectual property analytics. It highlights the platform's high-quality data and knowledge-based support services without detailing specific clinical findings or study methodologies. Relevance to endometriosis: listed as one indication for LHRH antagonists in the patent scope, though the paper's main focus is on intellectual property valuation tools rather than medical research.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works